Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc AGNPF


Primary Symbol: C.AGN

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

Algernon Pharmaceuticals Inc > Recent News
View:
Post by SkywalkerofLuke on Jan 16, 2023 5:03pm

Recent News

After completing the Phase 2a study of Ifenprodil and seeing significant positive results, AGN.c AGNPF announced last week a 180 patient, 90-day Phase 2b clinical study of Ifenprodil for chronic cough to begin in Q3.


As Jacky Smith, Professor of Respiratory Medicine at the University of Manchester, stated, “I am very pleased Algernon has decided to conduct a stand-alone, Phase 2b study for cough . . . based on Algernon’s encouraging Phase 2a clinical data.” 


The chronic cough market is expected to reach $11.38B by 2029 and with AGN planning to file an investigational new drug application with the FDA shortly, I’m watching AGN.


https://www.youtube.com/watch?v=REtP6b3LwY0

Be the first to comment on this post
Algernon Pharmaceuticals Inc